Stocktoria
ROCKET PHARMACEUTICALS, INC. RCKT
ROCKET PHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $142.0M | $171.2M | $186.3M | $165.6M | $125.5M | $105.4M | $57.9M | $53.3M | $14.9M | $6.0M |
| Operating income | -$231.7M | -$273.2M | -$259.7M | -$224.3M | -$167.2M | -$134.3M | -$76.2M | -$71.2M | -$19.8M | -$7.6M |
| Interest expense | $1.9M | $1.9M | $1.9M | $1.9M | $3.0M | $7.0M | $6.0M | $6.0M | $0 | $0 |
| Income tax | $0 | $0 | $0 | — | — | — | — | — | — | — |
| Net income | -$223.1M | -$258.7M | -$245.6M | -$221.9M | -$169.1M | -$139.7M | -$77.3M | -$74.5M | -$19.6M | -$7.6M |
| EPS (diluted) | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 | $-2.52 | $-1.58 | — | — | — |
| Operating cash flow | -$190.0M | -$209.7M | -$194.9M | -$178.1M | -$121.2M | -$74.6M | -$64.7M | -$53.8M | -$26.1M | -$37.3M |
| Free cash flow | -$190.5M | -$215.6M | -$211.4M | -$186.5M | -$128.8M | -$95.2M | -$87.9M | -$55.2M | -$26.9M | -$37.6M |
| Cash & equivalents | $77.6M | $163.6M | $55.9M | $140.5M | $232.7M | $297.1M | $185.4M | $111.4M | $18.1M | $29.8M |
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M | $497.0M | $590.8M | $372.1M | $251.3M | $20.1M | $129.6M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M | $42.3M | $87.3M | $64.8M | $57.3M | $4.6M | $56.5M |
| Shareholders' equity | $277.2M | $463.2M | $492.6M | $489.7M | $454.7M | $503.5M | $307.3M | $194.0M | $15.5M | $8.4M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.